BeiGene Granted NMPA Approval to Treat World’s Most Prevalent Esophageal Cancer
Beijing-based biotechnology company, BeiGene, was granted approval by China’s National Medical Products Administration (NMPA) on April 15th to administer their novel anti-PD-1 antibody, tislelizumab, to patients with second-line esophageal squamous cell carcinoma (ESCC). ESCC is by far the world’s most pervasive esophageal cancer accounting for about 90% of roughly 456,000 recorded cases each year.
It's free! Log in now to read
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02